Targeting cancer metabolism - Aiming at a tumour's sweet-spot

Drug Discovery Today

Volumn 17, Issue 5-6, 2012, Pages 232-241

  Jones, Neil P ^a   Schulze, Almut ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b THE FRANCIS CRICK INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

6 DIAZO 5 OXONORLEUCINE; AMINOOXYACETIC ACID; ANTINEOPLASTIC AGENT; AZD 3965; BROMOPYRUVIC ACID; C 75; CAP 232; CPI 613; DEOXYGLUCOSE; DICHLOROACETIC ACID; FX 11; GLUCOSE 6 PHOSPHATE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; GLUCOSE TRANSPORTER 1; GLUTAMINASE; GSK 837149A; LACTATE DEHYDROGENASE; LONIDAMINE; METFORMIN; MPC 9528; OXAMIC ACID; OXYTHIAMINE; PHLORETIN; PRASTERONE; PROTEIN P53; PYRUVIC ACID DERIVATIVE; SB 204990; SODIUM GLUCOSE COTRANSPORTER 1; TARVAGENIX; TETRAHYDROLIPSTATIN; TLN 232; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CARCINOGENESIS; CELL METABOLISM; CELL SURVIVAL; COLORECTAL CANCER; DNA REPAIR; DOWN REGULATION; DRUG EFFICACY; ELECTRON TRANSPORT; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; GENE MUTATION; GLIOBLASTOMA; GLUCOSE 6 PHOSPHATE DEHYDROGENASE DEFICIENCY; GLYCOLYSIS; HEREDITARY LEIOMYOMATOSIS AND RENAL CELL CANCER SYNDROME; HUMAN; KIDNEY CANCER; LEIOMYOMATOSIS; LIPOGENESIS; MELANOMA; METABOLIC DISORDER; MOLECULARLY TARGETED THERAPY; NUCLEOTIDE METABOLISM; ONCOGENE; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PENTOSE PHOSPHATE CYCLE; REVIEW; RNA INTERFERENCE; SIGNAL TRANSDUCTION; STOMACH CANCER; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; UNSPECIFIED SIDE EFFECT; UPREGULATION;

DRUG DISCOVERY; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84857992195     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2011.12.017     Document Type: Review

References (135)

1. O. Warburg The metabolism of tumors in the body J. Gen. Physiol. 8 1927 519 530
2. M.G. Vander Heiden Understanding the Warburg effect: the metabolic requirements of cell proliferation Science 324 2009 1029 1033
3. W.H. Koppenol Otto Warburg's contributions to current concepts of cancer metabolism Nat. Rev. Cancer 11 2011 325 337
4. E. Racker Bioenergetics and the problem of tumor growth Am. Sci. 60 1972 56 63
5. R.A. Cairns Regulation of cancer cell metabolism Nat. Rev. Cancer 11 2011 85 95
6. C.V. Dang Glutaminolysis: supplying carbon or nitrogen or both for cancer cells? Cell Cycle 9 2010 3884 3886
7. D.R. Wise, and C.B. Thompson Glutamine addiction: a new therapeutic target in cancer Trends Biochem. Sci. 35 2010 427 433
8. C.V. Dang MYC-induced cancer cell energy metabolism and therapeutic opportunities Clin. Cancer Res. 15 2009 6479 6483
9. P. Gao c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism Nature 458 2009 762 765
10. C.V. Dang Rethinking the Warburg effect with Myc micromanaging glutamine metabolism Cancer Res. 70 2010 859 862
11. D.R. Wise Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction Proc. Natl. Acad. Sci. U.S.A. 105 2008 18782 18787
12. J.J. Collier c-Myc is required for the glucose-mediated induction of metabolic enzyme genes J. Biol. Chem. 278 2003 6588 6595
13. Q. Sun Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth Proc Natl Acad. Sci. U.S.A. 108 2011 4129 4134
14. G.L. Semenza HIF-1: upstream and downstream of cancer metabolism Curr. Opin. Genet. Dev. 20 2010 51 56
15. R.C. Osthus Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc J. Biol. Chem. 275 2000 21797 21800
16. J.W. Kim Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1 Mol. Cell Biol. 27 2007 7381 7393
17. K. Podar, and K.C. Anderson A therapeutic role for targeting c-Myc/Hif-1-dependent signaling pathways Cell Cycle 9 2010 1722 1728
18. B.C. Lewis Tumor induction by the c-Myc target genes rcl and lactate dehydrogenase A Cancer Res. 60 2000 6178 6183
19. H. Shim c-Myc transactivation of LDH-A: implications for tumor metabolism and growth Proc. Natl. Acad. Sci. U.S.A. 94 1997 6658 6663
20. V.R. Fantin Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance Cancer Cell 9 2006 425 434
21. T.L. Yuan, and L.C. Cantley PI3K pathway alterations in cancer: variations on a theme Oncogene 27 2008 5497 5510
22. R.L. Elstrom Akt stimulates aerobic glycolysis in cancer cells Cancer Res. 64 2004 3892 3899
23. R.B. Robey, and N. Hay Is Akt the Warburg kinase''?-Akt-energy metabolism interactions and oncogenesis Semin. Cancer Biol. 19 2009 25 31
24. N. Majewski Hexokinase-mitochondria interaction mediated by Akt is required to inhibit apoptosis in the presence or absence of Bax and Bak Mol. Cell 16 2004 819 830
25. X. Tong The molecular determinants of de novo nucleotide biosynthesis in cancer cells Curr. Opin. Genet. Dev. 19 2009 32 37
26. R. Zoncu mTOR: from growth signal integration to cancer, diabetes and ageing Nat. Rev. Mol. Cell Biol. 12 2011 21 35
27. Y. Fan Akt and c-Myc differentially activate cellular metabolic programs and prime cells to bioenergetic inhibition J. Biol. Chem. 285 2010 7324 7333
28. R.J. DeBerardinis The biology of cancer: metabolic reprogramming fuels cell growth and proliferation Cell Metab. 7 2008 11 20
29. T. Porstmann PKB/Akt induces transcription of enzymes involved in cholesterol and fatty acid biosynthesis via activation of SREBP Oncogene 24 2005 6465 6481
30. Semenza, G.L. (2011) Regulation of metabolism by hypoxia-inducible factor 1. Cold Spring Harb Symp. Quant. Biol. Published in Advance 2011, doi:10.1101/sqb.2011.76.010678.
31. C.V. Dang The interplay between MYC and HIF in the Warburg effect Ernst Schering Found. Symp. Proc. 4 2007 35 53
32. J.D. Gordan HIF and c-Myc: sibling rivals for control of cancer cell metabolism and proliferation Cancer Cell 12 2007 108 113
33. W.G. Kaelin Jr. The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer Nat. Rev. Cancer 8 2008 865 873
34. M. Obach 6-Phosphofructo-2-kinase (pfkfb3) gene promoter contains hypoxia-inducible factor-1 binding sites necessary for transactivation in response to hypoxia J. Biol. Chem. 279 2004 53562 53570
35. A.Y. Bobarykina Hypoxic regulation of PFKFB-3 and PFKFB-4 gene expression in gastric and pancreatic cancer cell lines and expression of PFKFB genes in gastric cancers Acta Biochim. Pol. 53 2006 789 799
36. M.I. Koukourakis Pyruvate dehydrogenase and pyruvate dehydrogenase kinase expression in non small cell lung cancer and tumor-associated stroma Neoplasia 7 2005 1 6
37. H. Boulahbel Prolyl hydroxylases as regulators of cell metabolism Biochem. Soc. Trans. 37 2009 291 294
38. J.D. Firth Hypoxic regulation of lactate dehydrogenase A. Interaction between hypoxia-inducible factor 1 and cAMP response elements J. Biol. Chem. 270 1995 21021 21027
39. J.C. Maher Hypoxia-inducible factor-1 confers resistance to the glycolytic inhibitor 2-deoxy-d-glucose Mol. Cancer Ther. 6 2007 732 741
40. P.J. Pollard Targeted inactivation of fh1 causes proliferative renal cyst development and activation of the hypoxia pathway Cancer Cell 11 2007 311 319
41. M.L. Macheda Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer J. Cell Physiol. 202 2005 654 662
42. E. Furuta Metabolic genes in cancer: their roles in tumor progression and clinical implications Biochim Biophys. Acta 1805 2010 141 152
43. P.L. Pedersen Warburg, me and Hexokinase 2: multiple discoveries of key molecular events underlying one of cancers' most common phenotypes, the "Warburg Effect", i.e., elevated glycolysis in the presence of oxygen J. Bioenerg. Biomembr. 39 2007 211 222
44. S. Mazurek Pyruvate kinase type M2: a key regulator within the tumour metabolome and a tool for metabolic profiling of tumours Ernst Schering Found. Symp. Proc. 4 2007 99 124
45. V. Gupta, and R.N. Bamezai Human pyruvate kinase M2: a multifunctional protein Protein Sci. 19 2010 2031 2044
46. C.V. Dang PKM2 tyrosine phosphorylation and glutamine metabolism signal a different view of the Warburg effect Sci. Signal. 2 2009 75
47. H.R. Christofk The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth Nature 452 2008 230 233
48. H.R. Christofk Pyruvate kinase M2 is a phosphotyrosine-binding protein Nature 452 2008 181 186
49. T. Hitosugi Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth Sci. Signal. 2 2009 73
50. R.J. DeBerardinis Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis Proc. Natl. Acad. Sci. U.S.A. 104 2007 19345 19350
51. P.J. Pollard The TCA cycle and tumorigenesis: the examples of fumarate hydratase and succinate dehydrogenase Ann. Med. 35 2003 632 639
52. C. Frezza Inborn and acquired metabolic defects in cancer J. Mol. Med. (Berl.) 89 2011 213 220
53. C. Bardella SDH mutations in cancer Biochim. Biophys. Acta 1807 2011 432 443
54. P.J. Pollard Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations Hum. Mol. Genet. 14 2005 2231 2239
55. U. Srirangalingam Clinical manifestations of familial paraganglioma and phaeochromocytomas in succinate dehydrogenase B (SDH-B) gene mutation carriers Clin. Endocrinol. (Oxf.) 69 2008 587 596
56. U. Srirangalingam Contrasting clinical manifestations of SDHB and VHL associated chromaffin tumours Endocr. Relat. Cancer 16 2009 515 525
57. M.A. Selak Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase Cancer Cell 7 2005 77 85
58. T. Ahvenainen Mutation screening of fumarate hydratase by multiplex ligation-dependent probe amplification: detection of exonic deletion in a patient with leiomyomatosis and renal cell cancer Cancer Genet. Cytogenet. 183 2008 83 88
59. N.A. Alam Genetic and functional analyses of FH mutations in multiple cutaneous and uterine leiomyomatosis, hereditary leiomyomatosis and renal cancer, and fumarate hydratase deficiency Hum. Mol. Genet. 12 2003 1241 1252
60. D.A. Tennant Reactivating HIF prolyl hydroxylases under hypoxia results in metabolic catastrophe and cell death Oncogene 28 2009 4009 4021
61. M.E. Figueroa Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation Cancer Cell 18 2010 553 567
62. C. Frezza IDH1 mutations in gliomas: when an enzyme loses its grip Cancer Cell 17 2010 7 9
63. K.E. Yen Cancer-associated IDH mutations: biomarker and therapeutic opportunities Oncogene 29 2010 6409 6417
64. H. Yan IDH1 and IDH2 mutations in gliomas N. Engl. J. Med. 360 2009 765 773
65. S. Gross Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations J. Exp. Med. 207 2010 339 344
66. L. Dang Cancer-associated IDH1 mutations produce 2-hydroxyglutarate Nature 462 2009 739 744
67. P.S. Ward The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate Cancer Cell 17 2010 225 234
68. Y. Kekec Antioxidant enzyme levels in cases with gastrointesinal cancer Eur. J. Intern. Med. 20 2009 403 406
69. S. Langbein Metastasis is promoted by a bioenergetic switch: new targets for progressive renal cell cancer Int. J. Cancer 122 2008 2422 2428
70. P. Jiang p53 regulates biosynthesis through direct inactivation of glucose-6-phosphate dehydrogenase Nat. Cell Biol. 13 2011 310 316
71. C. Cosentino ATM activates the pentose phosphate pathway promoting anti-oxidant defence and DNA repair EMBO J. 30 2011 546 555
72. M. Pisano Glucose-6-phosphate dehydrogenase deficiency and lung cancer: a hospital based case-control study Tumorigenesis 77 1991 12 15
73. J.F. Coy Mutations in the transketolase-like gene TKTL1: clinical implications for neurodegenerative diseases, diabetes and cancer Clin. Lab. 51 2005 257 273
74. M. Foldi Transketolase protein TKTL1 overexpression: a potential biomarker and therapeutic target in breast cancer Oncol. Rep. 17 2007 841 845
75. X. Xu Transketolase-like protein 1 (TKTL1) is required for rapid cell growth and full viability of human tumor cells Int. J. Cancer 124 2009 1330 1337
76. A. Mayer Evidence against a major role for TKTL-1 in hypoxic and normoxic cancer cells Adv. Exp. Med. Biol. 701 2011 123 128
77. A. Mayer Glucose metabolism of malignant cells is not regulated by transketolase-like (TKTL)-1 Int. J. Oncol. 37 2010 265 271
78. L. Mitschke The crystal structure of human transketolase and new insights into its mode of action J. Biol. Chem. 285 2010 31559 31570
79. K. Bensaad TIGAR, a p53-inducible regulator of glycolysis and apoptosis Cell 126 2006 107 120
80. Gottlieb, E. and Vousden, K.H. (2009) p53 regulation of metabolic pathways. Cold Spring Harb. Perspect. Biol. 2, Abstr. 001040
81. K. Bensaad Modulation of intracellular ROS levels by TIGAR controls autophagy EMBO J. 28 2009 3015 3026
82. K.H. Vousden, and K.M. Ryan p53 and metabolism Nat. Rev. Cancer 9 2009 691 700
83. K. Snell Enzymic imbalance in serine metabolism in human colon carcinoma and rat sarcoma Br. J. Cancer 57 1988 87 90
84. J.W. Locasale Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis Nat. Genet. 43 2011 869 874
85. R. Possemato Functional genomics reveal that the serine synthesis pathway is essential in breast cancer Nature 476 2011 346 350
86. S. Pollari Enhanced serine production by bone metastatic breast cancer cells stimulates osteoclastogenesis Breast Cancer Res. Treat. 125 2011 421 430
87. T.J. de Koning, and L.W. Klomp Serine-deficiency syndromes Curr. Opin. Neurol. 17 2004 197 204
88. C.E. Hart Phosphoserine aminotransferase deficiency: a novel disorder of the serine biosynthesis pathway Am. J. Hum. Genet. 80 2007 931 937
89. L.W. Klomp Molecular characterization of 3-phosphoglycerate dehydrogenase deficiency - a neurometabolic disorder associated with reduced l-serine biosynthesis Am. J. Hum. Genet. 67 2000 1389 1399
90. T.J. de Koning Treatment with amino acids in serine deficiency disorders J. Inherit. Metab. Dis. 29 2006 347 351
91. D.A. Tennant Targeting metabolic transformation for cancer therapy Nat. Rev. Cancer 10 2010 267 277
92. H. Pelicano Glycolysis inhibition for anticancer treatment Oncogene 25 2006 4633 4646
93. N. Hammoudi Metabolic alterations in cancer cells and therapeutic implications Chin. J. Cancer 30 2011 508 525
94. J.K. Jiang Evaluation of thieno[3,2-b]pyrrole[3,2-d]pyridazinones as activators of the tumor cell specific M2 isoform of pyruvate kinase Bioorg. Med. Chem. Lett. 20 2010 3387 3393
95. W. Luo, and G.L. Semenza Pyruvate kinase M2 regulates glucose metabolism by functioning as a coactivator for hypoxia-inducible factor 1 in cancer cells Oncotarget 2 2011 551 556
96. L. Lv Acetylation targets the M2 isoform of pyruvate kinase for degradation through chaperone-mediated autophagy and promotes tumor growth Mol. Cell 42 2011 719 730
97. M.G. Vander Heiden Identification of small molecule inhibitors of pyruvate kinase M2 Biochem. Pharmacol. 79 2010 1118 1124
98. B. Clem Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth Mol. Cancer Ther. 7 2008 110 120
99. M.J. Seltzer Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1 Cancer Res. 70 2010 8981 8987
100. J. Fang The H+-linked monocarboxylate transporter (MCT1/SLC16A1): a potential therapeutic target for high-risk neuroblastoma Mol. Pharmacol. 70 2006 2108 2115
101. W.R. Mann Diverse mechanisms of inhibition of pyruvate dehydrogenase kinase by structurally distinct inhibitors Biochim. Biophys. Acta 1480 2000 283 292
102. J.M. Thornburg Targeting aspartate aminotransferase in breast cancer Breast Cancer Res. 10 2008 84
103. H. Liu Fructose induces transketolase flux to promote pancreatic cancer growth Cancer Res. 70 2010 6368 6376
104. F.P. Kuhajda Fatty acid synthase and cancer: new application of an old pathway Cancer Res. 66 2006 5977 5980
105. Y. Zhan Control of cell growth and survival by enzymes of the fatty acid synthesis pathway in HCT-116 colon cancer cells Clin. Cancer Res. 14 2008 5735 5742
106. G. Hatzivassiliou ATP citrate lyase inhibition can suppress tumor cell growth Cancer Cell 8 2005 311 321
107. D.K. Nomura Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis Cell 140 2010 49 61
108. L. Ye Monoacylglycerol lipase (MAGL) knockdown inhibits tumor cells growth in colorectal cancer Cancer Lett. 307 2011 6 17
109. M. Watson The small molecule GMX1778 is a potent inhibitor of NAD+ biosynthesis: strategy for enhanced therapy in nicotinic acid phosphoribosyltransferase 1-deficient tumors Mol. Cell Biol. 29 2009 5872 5888
110. G. Zoppoli Potent synergistic interaction between the Nampt inhibitor APO866 and the apoptosis activator TRAIL in human leukemia cells Exp. Hematol. 38 2010 979 988
111. E. Gottlieb Cancer: the fat and the furious Nature 461 2009 44 45
112. D. Singh Optimizing cancer radiotherapy with 2-deoxy-d-glucose dose escalation studies in patients with glioblastoma multiforme Strahlenther. Onkol. 181 2005 507 514
113. V.K. Prasanna Differential responses of tumors and normal brain to the combined treatment of 2-DG and radiation in glioablastoma J Cancer Res. Ther. 5 Suppl. 1 2009 44 47
114. B.S. Dwarakanath Clinical studies for improving radiotherapy with 2-deoxy-d-glucose: present status and future prospects J Cancer Res. Ther. 5 Suppl. 1 2009 21 26
115. S. Bonnet A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth Cancer Cell 11 2007 37 51
116. I. Papandreou Anticancer drugs that target metabolism: is dichloroacetate the new paradigm? Int. J. Cancer 128 2011 1001 1008
117. R.M. Mayers AZD7545, a novel inhibitor of pyruvate dehydrogenase kinase 2 (PDHK2), activates pyruvate dehydrogenase in vivo and improves blood glucose control in obese (fa/fa) Zucker rats Biochem. Soc. Trans. 31 2003 1165 1167
118. J.A. Morrell AZD7545 is a selective inhibitor of pyruvate dehydrogenase kinase 2 Biochem. Soc. Trans. 31 2003 1168 1170
119. G.L. Semenza Tumor metabolism: cancer cells give and take lactate J. Clin. Invest. 118 2008 3835 3837
120. K.M. Kennedy, and M.W. Dewhirst Tumor metabolism of lactate: the influence and therapeutic potential for MCT and CD147 regulation Future Oncol. 6 2010 127 148
121. P. Sonveaux Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice J. Clin. Invest. 118 2008 3930 3942
122. N. Pertega-Gomes Monocarboxylate transporter 4 (MCT4) and CD147 overexpression is associated with poor prognosis in prostate cancer BMC Cancer 11 2011 312
123. C. Pinheiro Monocarboxylate transporter 1 is up-regulated in basal-like breast carcinoma Histopathology 56 2010 860 867
124. C. Pinheiro Increasing expression of monocarboxylate transporters 1 and 4 along progression to invasive cervical carcinoma Int. J. Gynecol. Pathol. 27 2008 568 574
125. C. Pinheiro Increased expression of monocarboxylate transporters 1, 2, and 4 in colorectal carcinomas Virchows. Arch. 452 2008 139 146
126. C. Pinheiro Expression of monocarboxylate transporters 1, 2, and 4 in human tumours and their association with CD147 and CD44 J. Biomed. Biotechnol. 2010 2010 427694
127. K. Fischer Inhibitory effect of tumor cell-derived lactic acid on human T cells Blood 109 2007 3812 3819
128. H. Izumi Monocarboxylate transporters 1 and 4 are involved in the invasion activity of human lung cancer cells Cancer Sci. 102 2011 1007 1013
129. M.J. Birnbaum, and R.J. Shaw Genomics: drugs, diabetes and cancer Nature 470 2011 338 339
130. D.G. Hardie AMP-activated protein kinase: a cellular energy sensor with a key role in metabolic disorders and in cancer Biochem. Soc. Trans. 39 2011 1 13
131. S. Bo Cancer mortality reduction and metformin. A retrospective cohort study in type 2 diabetic patients Diabetes Obes. Metab. 14 2012 23 29
132. S.L. Bowker Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin Diabetes Care 29 2006 254 258
133. J.M. Evans Metformin and reduced risk of cancer in diabetic patients BMJ 330 2005 1304 1305
134. R.J. Shaw The LKB1 tumor suppressor negatively regulates mTOR signaling Cancer Cell 6 2004 91 99
135. R.J. Shaw The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress Proc. Natl. Acad. Sci. U.S.A. 101 2004 3329 3335